Lilly exclusive worldwide rights to RRMS and SPMS compound, MBP8298
Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for the Treatment of Multiple ... more »
|
|||
|
Multiple Sclerosis Info
If you want this blog to continue, than make it financialy viable for Bonnie to continue it. She puts in 2-3 hours a day into this blog, and spends money on it for it's upkeep.
Search
This Month
|
Sunday, December 30
Lilly has exclusive rights to RRMS and SPMS compound, MBP8298
by
All About MS
on Sun 30 Dec 2007 08:44 PM CST
Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For RRMS
by
All About MS
on Sun 30 Dec 2007 09:18 AM CST
Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis
Teva Pharmaceutical Industries Ltd. ... more » Saturday, December 15
How effective are disease-modifying drugs in delaying progression
by
All About MS
on Sat 15 Dec 2007 12:00 AM CST
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Capital Health District, Nova Scotia, Canada.
Our objective ... more » Thursday, December 13
Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis
by
All About MS
on Thu 13 Dec 2007 08:00 AM CST
Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis An Open-Label Trial Objective To evaluate the efficacy, safety, and tolerabilityof combination therapy with ... more » Sunday, December 9
Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
by
All About MS
on Sun 09 Dec 2007 12:00 AM CST
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis Three-Year Analysis Demonstrates Robust, Highly Statistically Significant Treatment Effect of Alemtuzumab ... more » |
||